FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2730951905> ?p ?o ?g. }

• W2730951905 endingPage "e116" @default.
• W2730951905 startingPage "1158" @default.
• W2730951905 abstract "There continues to be a lack of systemic options for advanced hepatocellular carcinoma (HCC); sorafenib and, very recently, regorafenib are the only approved options. There exists a potential to combine sorafenib with chemotherapeutic agents shown to be active in HCC, such as capecitabine, safely.Good tumor response was observed, with objective improvement in a few patients seldom seen by single agent sorafenib; however, because of the limited number of patients, meaningful conclusions on survival cannot be drawn.Sorafenib is the currently approved first-line treatment for hepatocellular carcinoma (HCC). Capecitabine has antitumor activity in hepatobiliary cancers. The combination of the two, if tolerated, could possibly improve antitumor response, and survival.Patients with advanced HCC ineligible for locoregional therapy, Eastern Cooperative Oncology Group performance status of ≤2, Child-Pugh class A or B-7 cirrhosis, hemoglobin ≥8.5 g/dL, platelets ≥50,000/μL, absolute neutrophil count (ANC) ≥1,500 cells/μL, and serum creatinine of ≤2.0 mg/dL were recruited. All subjects received a combination of sorafenib and capecitabine, on a 14-day 7-days on 7-days off schedule. The primary end point was safety and secondary end points were overall survival (OS) and disease control rate.A total of 15 out of 47 patients met inclusion criteria. Median age was 64 years (56-79) and 77% were male. With a median follow-up of 12 months, median OS was 12.7 months (95% confidence interval [CI], 8.5-23.4). Disease control rate was 77% (complete response 8%, partial response 8%, and stable disease 61%). Common adverse events were as follows: (a) thrombocytopenia (64%); (b) anemia (14%); (c) hypophosphatemia (21%); (d) hypomagnesemia (14%); (e) hyperbilirubinemia (21%); (f) increased aspartate transaminase (AST) (14%); (g) hand-foot syndrome (21%); and (h) deep vein thrombosis (21%).At tolerable doses, the combination of sorafenib and capecitabine seems an active and safe palliative treatment for HCC in class A and B-7 patients with cirrhosis. The small sample size does not allow comparison with single-agent sorafenib." @default.
• W2730951905 created "2017-07-14" @default.
• W2730951905 creator A5016984184 @default.
• W2730951905 creator A5036496783 @default.
• W2730951905 creator A5036781090 @default.
• W2730951905 creator A5046413977 @default.
• W2730951905 creator A5064488553 @default.
• W2730951905 date "2017-07-07" @default.
• W2730951905 modified "2023-10-06" @default.
• W2730951905 title "Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20" @default.
• W2730951905 cites W1604740730 @default.
• W2730951905 cites W1970545762 @default.
• W2730951905 cites W1971837077 @default.
• W2730951905 cites W1998832059 @default.
• W2730951905 cites W2016155151 @default.
• W2730951905 cites W2021477734 @default.
• W2730951905 cites W2049811920 @default.
• W2730951905 cites W2080663543 @default.
• W2730951905 cites W2137813001 @default.
• W2730951905 cites W2156871508 @default.
• W2730951905 cites W2171541660 @default.
• W2730951905 cites W2616059838 @default.
• W2730951905 doi "https://doi.org/10.1634/theoncologist.2017-0168" @default.
• W2730951905 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5634773" @default.
• W2730951905 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28687627" @default.
• W2730951905 hasPublicationYear "2017" @default.
• W2730951905 type Work @default.
• W2730951905 sameAs 2730951905 @default.
• W2730951905 citedByCount "20" @default.
• W2730951905 countsByYear W27309519052018 @default.
• W2730951905 countsByYear W27309519052019 @default.
• W2730951905 countsByYear W27309519052020 @default.
• W2730951905 countsByYear W27309519052021 @default.
• W2730951905 countsByYear W27309519052022 @default.
• W2730951905 countsByYear W27309519052023 @default.
• W2730951905 crossrefType "journal-article" @default.
• W2730951905 hasAuthorship W2730951905A5016984184 @default.
• W2730951905 hasAuthorship W2730951905A5036496783 @default.
• W2730951905 hasAuthorship W2730951905A5036781090 @default.
• W2730951905 hasAuthorship W2730951905A5046413977 @default.
• W2730951905 hasAuthorship W2730951905A5064488553 @default.
• W2730951905 hasBestOaLocation W27309519051 @default.
• W2730951905 hasConcept C121608353 @default.
• W2730951905 hasConcept C126322002 @default.
• W2730951905 hasConcept C143998085 @default.
• W2730951905 hasConcept C203092338 @default.
• W2730951905 hasConcept C2776248978 @default.
• W2730951905 hasConcept C2776264508 @default.
• W2730951905 hasConcept C2776694085 @default.
• W2730951905 hasConcept C2776999253 @default.
• W2730951905 hasConcept C2777214474 @default.
• W2730951905 hasConcept C2777909004 @default.
• W2730951905 hasConcept C2778019345 @default.
• W2730951905 hasConcept C2778695046 @default.
• W2730951905 hasConcept C2778822529 @default.
• W2730951905 hasConcept C2779984678 @default.
• W2730951905 hasConcept C526805850 @default.
• W2730951905 hasConcept C535046627 @default.
• W2730951905 hasConcept C71924100 @default.
• W2730951905 hasConcept C90924648 @default.
• W2730951905 hasConceptScore W2730951905C121608353 @default.
• W2730951905 hasConceptScore W2730951905C126322002 @default.
• W2730951905 hasConceptScore W2730951905C143998085 @default.
• W2730951905 hasConceptScore W2730951905C203092338 @default.
• W2730951905 hasConceptScore W2730951905C2776248978 @default.
• W2730951905 hasConceptScore W2730951905C2776264508 @default.
• W2730951905 hasConceptScore W2730951905C2776694085 @default.
• W2730951905 hasConceptScore W2730951905C2776999253 @default.
• W2730951905 hasConceptScore W2730951905C2777214474 @default.
• W2730951905 hasConceptScore W2730951905C2777909004 @default.
• W2730951905 hasConceptScore W2730951905C2778019345 @default.
• W2730951905 hasConceptScore W2730951905C2778695046 @default.
• W2730951905 hasConceptScore W2730951905C2778822529 @default.
• W2730951905 hasConceptScore W2730951905C2779984678 @default.
• W2730951905 hasConceptScore W2730951905C526805850 @default.
• W2730951905 hasConceptScore W2730951905C535046627 @default.
• W2730951905 hasConceptScore W2730951905C71924100 @default.
• W2730951905 hasConceptScore W2730951905C90924648 @default.
• W2730951905 hasIssue "10" @default.
• W2730951905 hasLocation W27309519051 @default.
• W2730951905 hasLocation W27309519052 @default.
• W2730951905 hasLocation W27309519053 @default.
• W2730951905 hasLocation W27309519054 @default.
• W2730951905 hasOpenAccess W2730951905 @default.
• W2730951905 hasPrimaryLocation W27309519051 @default.
• W2730951905 hasRelatedWork W2392900588 @default.
• W2730951905 hasRelatedWork W2611336716 @default.
• W2730951905 hasRelatedWork W2806906789 @default.
• W2730951905 hasRelatedWork W2979385728 @default.
• W2730951905 hasRelatedWork W3031596504 @default.
• W2730951905 hasRelatedWork W4210955410 @default.
• W2730951905 hasRelatedWork W4240372685 @default.
• W2730951905 hasRelatedWork W4241130570 @default.
• W2730951905 hasRelatedWork W4313416471 @default.
• W2730951905 hasRelatedWork W9288866 @default.
• W2730951905 hasVolume "22" @default.
• W2730951905 isParatext "false" @default.
• W2730951905 isRetracted "false" @default.

• next